A Study Of The Safety And Effects Of One Or More Doses Of HSP-130 Injected Under The Skin In Women With Breast Cancer That Has Not Spread To Distant Sites In The Body.

• ClinicalTrials.gov Identifier: NCT02650193
• Recruitment Status: Completed
• First Posted: January 8, 2016
• Results First Posted: October 23, 2018
• Last Update Posted: October 23, 2018
• Sponsor: Pfizer
• Collaborator: Hospira, now a wholly owned subsidiary of Pfizer
• Information provided by (Responsible Party): Pfizer

Study Description

Brief Summary:

This is a study of how one or more injections of HSP-130 under the skin effect the white blood cell counts and drug levels in women with breast cancer that has not spread to distant sites in the body (non-metastatic). This will be studied in women before breast surgery or while receiving chemotherapy. Safety will also be studied.

Additionally, the purpose of this study is to evaluate the effects and safety of single and multiple doses of HSP-130 in subjects with non-metastatic breast cancer. This study will determine the dose to move forward for future clinical trials.

Condition or disease	Intervention/treatment	Phase
Non-metastatic Breast Cancer	Drug: HSP-130	Phase 2

Detailed Description:

This is an open-label, sequential enrollment study characterizing the pharmacodynamic (PD), pharmacokinetic (PK) and safety of HSP-130 in subjects with non-metastatic breast cancer who have not previously received chemotherapy at any point prior to enrollment in this study (ZIN-130-1504).

The purpose of this study is to evaluate the effects and safety of single and multiple doses of HSP-130 in subjects with non-metastatic breast cancer. This study will determine the dose to move forward for future clinical trials.

There are two aspects of the study. In the initial part of the study, 6 subjects will be sequentially enrolled to receive HSP-130 treatment (3 mg , or 6 mg by subcutaneous injection) during the period between biopsy and definitive surgery. This will determine whether 3 mg and 6 mg have similar or different effects on the PD variables (absolute neutrophil counts and CD34+ cell counts). This part of the study is referred to as Cycle 0 since study subjects will receive no chemotherapy while receiving HSP-130 until the effect of HSP-130 on the PD variables is known. A total of 12 subjects may be enrolled in Cycle 0.

The objective of Cycle 1-4 is to determine the dose to be taken forward to Phase 3 clinical trials. Cycles 1-4 subjects will receive HSP-130 after their definitive breast surgery at the time they receive TAC chemotherapy (docetaxel, doxorubicin, and cyclophosphamide). Subjects will receive up to 4 cycles of every 3 week TAC chemotherapy with HSP-130 given on Day 2 of the chemotherapy regimen.

• If the 3 mg dose is found to be inferior (potentially subtherapeutic) to the 6 mg dose in Cycle 0, only the 6 mg dose will be studied in Cycles 1-4 (n=12), when subjects receive concomitant chemotherapy.
• If the 3 mg dose is found to be comparable to the PD results obtained in Cycle 0 with 6 mg, the 3 mg dose (n=12) will also be studied in women receiving TAC chemotherapy.

Data from the HSP-130 6 mg regimen (plus 3 mg, as appropriate) will be analysed, discussed with the FDA and determination if a dose greater than 6 mg is appropriate to study (e.g., 12 mg). If all three doses are studied, a total enrollment of up to 36 subjects is projected for Cycles 1-4.

Study Design

• Study Type: Interventional (Clinical Trial)
• Actual Enrollment: 25 participants
• Intervention Model: Parallel Assignment
• Masking: None (Open Label)
• Primary Purpose: Other
• Official Title: A Phase 1-2 Ascending Dose Study To Assess The Pharmacodynamics, Pharmacokinetics, And Safety Of Hsp-130 In Subjects With Non-metastatic Breast Cancer Following Single-dose And Multiple-dose Administration By Subcutaneous Injection
• Actual Study Start Date: December 2015
• Actual Primary Completion Date: October 2017
• Actual Study Completion Date: October 2017

Arms and Interventions

Arm

Intervention/treatment

Experimental: HSP-130; Cycle 0: Regimen A: HSP 130, 3 mg, single SC injection in the deltoid region (n = 6) Regimen B: HSP 130, 6 mg, single SC injection in the deltoid region (n = 6) Cycles 1-4: Regimen B (n = 12): HSP 130, 6 mg, single SC injection in the deltoid region, at least 24 hours after administration of chemotherapy in Cycle 1, Cycle 2, Cycle 3, and Cycle 4. Potential Regimen A (n = 12): 3 mg with background chemotherapy: Inclusion of this cohort will be based on assessment of comparability between Regimens A and B in Cycle 0 for ANC and CD34+ as defined above. If performed, this regimen will be HSP 130, 3 mg, single SC injection in the deltoid region, at least 24 hours after administration of chemotherapy in Cycle 1, Cycle 2, Cycle 3, and Cycle 4, as appropriate. Conditional Regimen C (12 mg):This cohort will not be initiated until data from cycle 0 for 3 mg and 6 mg and Cycles 1-4 for 6 mg has been reviewed and analyzed.

Drug: HSP-130; Dosage will vary per each cohort: (Five independent cohorts) Cycle 0 Regimen A - 3 mg Cycle 0 Regimen B - 6 mg Cycles 1-4 Regimen B - 6 mg Cycles 1-4 Regimen A (Potential)- 3 mg Cycles 1-4 Regimen C (Conditional)- 12 mg; Other Name: Pegylated filgrastim

Outcome Measures

Primary Outcome Measures :

1. Area Under the Effect Curve for Absolute Neutrophil Count (AUECANC): Cycle 0 [ Time Frame: Cycle 0: Predose (0 hour), 48, 96, 144, 192, 240 and 312 hours post-dose ]
   Absolute neutrophil count (ANC) is a measure of the number of neutrophil granulocytes (also known as polymorphonuclear cells, PMN's, polys, granulocytes, segmented neutrophils or segs) present in the blood.
2. Area Under the Serum Concentration Time Curve From Time of Dose Administration to Time Infinity (AUCinf): Cycle 0 [ Time Frame: Cycle 0: Predose (0 hour), 6, 12, 24, 48, 96, 144, 192, 240 and 312 hours post-dose ]
   AUCinf = Area under the serum concentration of HSP-130 versus time curve (AUC) from the time of dose administration to extrapolated infinite time (0-inf).
3. Maximum Observed Serum Concentration (Cmax): Cycle 0 [ Time Frame: Cycle 0: Predose (0 hour), 6, 12, 24, 48, 96, 144, 192, 240 and 312 hours post-dose ]
4. Duration of Severe Neutropenia (DSN): Cycle 1 [ Time Frame: Cycle 1: Predose (0 hour), 48, 96, 144, 192, 240 and 312 hours post-dose ]
   Severe Neutropenia was defined as grade 4 neutropenia in which the ANC was < 0.5 x10^9 per liter. DSN was defined as the days with grade 4 neutropenia (ANC < 0.5 x10^9/L).
5. Area Under the Serum Concentration Time Curve From Time of Dose Administration to Time of Last Measurable Concentration (AUCt): Cycle 1 and Cycle 4 [ Time Frame: Cycle 1 and 4: Predose (0 hour), 6, 12, 24, 48, 96, 144, 192, 240 and 312 hours post-dose ]
   AUC0-t= Area under the serum concentration of HSP-130 versus time curve from the time of dose administration to time of last quantifiable concentration (0-t).
6. Maximum Observed Serum Concentration (Cmax): Cycle 1 and Cycle 4 [ Time Frame: Cycle 1 and 4: Predose (0 hour), 6, 12, 24, 48, 96, 144, 192, 240 and 312 hours post-dose ]

Secondary Outcome Measures :

1. Maximum Effect for Absolute Neutrophil Count (ANC_Emax): Cycle 0 [ Time Frame: Cycle 0: Predose (0 hour), 48, 96, 144, 192, 240 and 312 hours post-dose ]
   ANC was a measure of the number of neutrophil granulocytes (also known as polymorphonuclear cells, PMN's, polys, granulocytes, segmented neutrophils or segs) present in the blood.
2. Time of Maximum Effect for Absolute Neutrophil Count (ANC_Tmax): Cycle 0 [ Time Frame: Cycle 0: Predose (0 hour), 48, 96, 144, 192, 240 and 312 hours post-dose ]
   ANC was a measure of the number of neutrophil granulocytes (also known as polymorphonuclear cells, PMN's, polys, granulocytes, segmented neutrophils or segs) present in the blood.
3. Area Under the Effect Curve for CD34+ (AUECCD34+): Cycle 0 [ Time Frame: Cycle 0: Predose (0 hour), 48, 96, 144, 192, 240 and 312 hours post-dose ]
4. Maximum Effect for CD34+ Count (CD34+_Emax): Cycle 0 [ Time Frame: Cycle 0: Predose (0 hour), 48, 96, 144, 192, 240 and 312 hours post-dose ]
5. Time of Maximum Effect for CD34+ Count (CD34+ Tmax): Cycle 0 [ Time Frame: Cycle 0: Predose (0 hour), 48, 96, 144, 192, 240 and 312 hours post-dose ]
6. Area Under the Effect Curve for Absolute Neutrophil Count From Time of Dose Administration to Time Infinity (AUEC_ANC Inf): Cycle 0 [ Time Frame: Cycle 0: Predose (0 hour), 48, 96, 144, 192, 240 and 312 hours post-dose ]
   ANC is a measure of the number of neutrophil granulocytes (also known as polymorphonuclear cells, PMN's, polys, granulocytes, segmented neutrophils or segs) present in the blood.
7. Area Under the Effect Curve From Time of Dose Administration to Time Infinity for CD34 + (AUEC_CD34+ Inf): Cycle 0 [ Time Frame: Cycle 0: Predose (0 hour), 48, 96, 144, 192, 240 and 312 hours post-dose ]
8. Area Under the Serum Concentration Time Curve From the Time of Dose Administration to the Time of Last Measurable Concentration (AUCt): Cycle 0 [ Time Frame: Cycle 0: Predose (0 hour), 6, 12, 24, 48, 96, 144, 192, 240 and 312 hours post-dose ]
   AUC0-t= Area under the serum concentration of HSP-130 versus time curve from the time of dose administration to time of last quantifiable concentration (0-t).
9. Time To Achieve Maximum Serum Concentration (Tmax): Cycle 0 [ Time Frame: Cycle 0: Predose (0 hour), 6, 12, 24, 48, 96, 144, 192, 240 and 312 hours post-dose ]
10. Elimination Half-Life (t1/2): Cycle 0 [ Time Frame: Cycle 0: Predose (0 hour), 6, 12, 24, 48, 96, 144, 192, 240 and 312 hours post-dose ]
    t1/2 is the time taken for plasma concentration of HSP 130 to reduce by 50 percent (%) of its initial value.
11. Elimination Rate Constant (λz): Cycle 0 [ Time Frame: Cycle 0: Predose (0 hour), 6, 12, 24, 48, 96, 144, 192, 240 and 312 hours post-dose ]
    Elimination rate constant was defined as the rate at which the drug was removed from the body.
12. Apparent Clearance (CL/F): Cycle 0 [ Time Frame: Cycle 0: Predose (0 hour), 6, 12, 24, 48, 96, 144, 192, 240 and 312 hours post-dose ]
    Clearance of a drug was defined as the rate at which a drug was metabolized or eliminated by normal biological processes.
13. Protein-Content Corrected Area Under the Serum Concentration Time Curve From Time of Dose Administration to Time Infinity (AUCinf): Cycle 0 [ Time Frame: Cycle 0: Predose (0 hour), 6, 12, 24, 48, 96, 144, 192, 240 and 312 hours post-dose ]
    The protein-content correction was conducted for AUCinf parameter: Protein-content corrected AUCinf = Nominal Protein-content AUCinf / (Actual protein concentration/10.0 mg/mL).
14. Protein-Content Corrected Area Under the Serum Concentration Time Curve From Time of Dose Administration to Time of Last Measurable Concentration (AUCt): Cycle 0 [ Time Frame: Cycle 0: Predose (0 hour), 6, 12, 24, 48, 96, 144, 192, 240 and 312 hours post-dose ]
    The protein-content correction was conducted for AUCt parameter: Protein-content corrected AUCt= Nominal Protein-content AUCt / (Actual protein concentration/10.0 mg/mL).
15. Protein-Content Corrected Maximum Observed Serum Concentration (Cmax): Cycle 0 [ Time Frame: Cycle 0: Predose (0 hour), 6, 12, 24, 48, 96, 144, 192, 240 and 312 hours post-dose ]
    The protein-content correction was conducted for Cmax parameter: Protein-content corrected Cmax = Nominal Protein-content Cmax / (Actual protein concentration/10.0 mg/mL).
16. Duration of Severe Neutropenia (DSN): Cycle 4 [ Time Frame: Cycle 4: Predose (0 hour), 48, 96, 144, 192, 240 and 312 hours post-dose ]
    Severe Neutropenia was defined as grade 4 neutropenia in which the ANC was < 0.5 x10^9/L. DSN was defined as the days with grade 4 neutropenia (ANC < 0.5 x10^9/L).
17. Absolute Neutrophil Count Nadir Concentration: Cycle 1 and Cycle 4 [ Time Frame: Cycle 1 and 4: Predose (0 hour), 48, 96, 144, 192, 240, and 312 hours post-dose ]
    Nadir was defined as the lowest count for ANC concentration reported after first dose of study treatment.
18. Time of ANC Nadir Concentration: Cycle 1 and Cycle 4 [ Time Frame: Cycle 1 and 4: Predose (0 hour), 48, 96, 144, 192, 240, and 312 hours post-dose ]
    Time of ANC Nadir (in hours) was defined as the time from the first dose of study treatment on Day 2 of Cycle 1 and 4 to the time the lowest value was recorded.
19. Area Under the Effect Curve (AUEC_ANCt): Cycle 1 and Cycle 4 [ Time Frame: Cycle 1 and 4: Predose (0 hour), 48, 96, 144, 192, 240, and 312 hours post-dose ]
    ANC is a measure of the number of neutrophil granulocytes (also known as polymorphonuclear cells, PMN's, polys, granulocytes, segmented neutrophils or segs) present in the blood.
20. Area Under the Effect Curve for Absolute Neutrophil Count From Time of Dose Administration to Time Infinity (AUEC_ANC Inf): Cycle 1 and Cycle 4 [ Time Frame: Cycle 1 and 4: Predose (0 hour), 48, 96, 144, 192, 240 and 312 hours post-dose ]
    Absolute neutrophil count (ANC) is a measure of the number of neutrophil granulocytes (also known as polymorphonuclear cells, PMN's, polys, granulocytes, segmented neutrophils or segs) present in the blood.
21. Incidence of Febrile Neutropenia: Cycle 1 and Cycle 4 [ Time Frame: Cycle 1 and 4: Predose (0 hour), 48, 96, 144, 192, 240 and 312 hours post-dose ]
    Febrile Neutropenia was defined as tympanic or axillary body temperature greater than (>) 38.5 °C for >1 hour and ANC less than (<) 1.0 *10^9/L.
22. Incidence of Severe Neutropenia: Cycle 1 and Cycle 4 [ Time Frame: Cycle 1 and 4: Predose (0 hour), 48, 96, 144, 192, 240, and 312 hours post-dose ]
    Severe Neutropenia was defined as grade 4 neutropenia in which the ANC was < 0.5 x10^9/L.
23. Time to ANC Recovery: Cycle 1 and Cycle 4 [ Time Frame: Cycle 1 and 4: Predose (0 hour), 48, 96, 144, 192, 240 and 312 hours post-dose ]
    Time to ANC recovery was defined as the time from documentation of the first day with ANC greater than equal to (>=) 2.0 x10^9/L after any day with ANC <2.0 x10^9/L.
24. Area Under the Serum Concentration Time Curve From Time of Dose Administration to Time Infinity (AUCinf): Cycle 1 and Cycle 4 [ Time Frame: Cycle 1 and 4: Predose (0 hour), 6, 12, 24, 48, 96, 144, 192, 240 and 312 hours post-dose ]
    AUC0-inf = Area under the serum concentration versus time curve (AUC) from the time of dose administration to extrapolated infinite time (0-inf).
25. Time To Achieve Maximum Serum Concentration (Tmax): Cycle 1 and Cycle 4 [ Time Frame: Cycle 1 and 4: Predose (0 hour), 6, 12, 24, 48, 96, 144, 192, 240 and 312 hours post-dose ]
26. Elimination Half-Life (t1/2): Cycle 1 and Cycle 4 [ Time Frame: Cycle 1 and 4: Predose (0 hour), 6, 12, 24, 48, 96, 144, 192, 240 and 312 hours post-dose ]
    t1/2 is the time taken for plasma concentration of a drug to reduce by 50% of its initial value.
27. Elimination Rate Constant (λz): Cycle 1 and Cycle 4 [ Time Frame: Cycle 1 and 4: Predose (0 hour), 6, 12, 24, 48, 96, 144, 192, 240 and 312 hours post-dose ]
    Elimination rate constant was defined as the rate at which the drug was removed from the body.
28. Apparent Clearance (CL/F): Cycle 1 and Cycle 4 [ Time Frame: Cycle 1 and 4: Predose (0 hour), 6, 12, 24, 48, 96, 144, 192, 240 and 312 hours post-dose ]
    CL/F was defined as a quantitative measure of the rate at which a drug substance is removed from the body.
29. Protein-Content Corrected Area Under the Serum Concentration Time Curve From Time of Dose Administration to Time of Last Measurable Concentration (AUCt): Cycle 1 and Cycle 4 [ Time Frame: Cycle 1 and 4: Predose (0 hour), 6, 12, 24, 48, 96, 144, 192, 240 and 312 hours post-dose ]
    The protein-content correction was conducted for AUCt parameter: Protein-content corrected AUCt= Nominal Protein-content AUCt / (Actual protein concentration/10.0 mg/mL).
30. Protein-Content Corrected Area Under the Serum Concentration Time Curve From Time of Dose Administration to Time Infinity (AUCinf): Cycle 1 and Cycle 4 [ Time Frame: Cycle 1 and 4: Predose (0 hour), 6, 12, 24, 48, 96, 144, 192, 240 and 312 hours post-dose ]
    The protein-content correction was conducted for AUCinf parameter: Protein-content corrected AUCinf = Nominal Protein-content AUCinf / (Actual protein concentration/10.0 mg/mL).
31. Protein-Content Corrected Maximum Observed Serum Concentration (Cmax): Cycle 1 and Cycle 4 [ Time Frame: Cycle 1 and 4: Predose (0 hour), 6, 12, 24, 48, 96, 144, 192, 240 and 312 hours post-dose ]
    The protein-content correction was conducted for Cmax parameter: Protein-content corrected Cmax = Nominal Protein-content Cmax / (Actual protein concentration/10.0 mg/mL).

Other Outcome Measures:

1. Number of Participants With Treatment-Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs) [ Time Frame: Baseline up to approximately Day 94 ]
   An AE was any untoward medical occurrence in participants who received study drug without regard to possibility of causal relationship. SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. Treatment Emergent Adverse Event (TEAE) was adverse event that started or worsened in severity after the HSP-130 administration up to and including 30 days post HSP-130 administration (up to Day 94). AEs included both serious and non-serious.
2. Number of Participants With Treatment-Emergent Adverse Events (AEs) of Special Interest [ Time Frame: Baseline up to approximately Day 94 ]
   AEs of Special Interest (AESI) included Potential Allergic Reactions, Splenomegaly, Splenic Rupture, Acute Respiratory Distress Syndrome, Alveolar Hemorrhage, Hemoptysis, Leukocytosis, Thrombocytopenia, Capillary Leak Syndrome, Cytokine Release Syndrome, Cutaneous Vasculitis and Glomerulonephritis.
3. Number of Participants With Laboratory Abnormalities [ Time Frame: Baseline up to approximately Day 94 ]
   Criteria: hematology (hemoglobin, hematocrit, platelet count, white blood cell count, neutrophils); chemistry (alkaline phosphatase, glucose, lactate dehydrogenase, alanine aminotransferase, aspartate aminotransferase, albumin, creatinine and gamma-glutamyl transpeptidase, blood urea nitrogen, total protein, phosphate, and uric acid); urinalysis. The clinical laboratory results and patterns observed were consistent with the known therapeutic response and the safety profile for the US and EU approved pegylated filgrastim (Neulasta).
4. Number of Participants With Clinically Significant Vital Sign Abnormalities [ Time Frame: Baseline up to approximately Day 94 ]
   Vital sign assessment included body temperature (tympanic or axillary), heart rate (sitting), blood pressure (sitting systolic and diastolic), and respiratory rate. Clinically significant abnormality was based upon investigator's discretion.
5. Number of Participants With Clinically Significant Physical Examination Abnormalities [ Time Frame: Baseline up to approximately Day 94 ]
   Physical examination included physical assessment of the spleen. Clinically significant abnormality was based on investigator's discretion.
6. Number of Participants With Clinically Significant Electrocardiogram (ECG) Abnormalities [ Time Frame: Baseline up to approximately Day 94 ]
   Clinically significant abnormality was based upon investigator's discretion.
7. Number of Participants With At Least 1 Concomitant Medication [ Time Frame: Baseline up to approximately Day 94 ]
8. Duration of Exposure to Study Drug Medication [ Time Frame: Baseline up to approximately Day 94 ]
9. Number of Participants With Positive Anti-pegfilgrastim (Anti-drug) Antibodies [ Time Frame: Baseline up to approximately Day 94 ]

Eligibility Criteria

• Ages Eligible for Study: 18 Years and older (Adult, Older Adult)
• Sexes Eligible for Study: Female
• Gender Based Eligibility: Yes
• Accepts Healthy Volunteers: No

Criteria

Inclusion Criteria:

• A subject will be eligible for study participation if all of the following criteria are met at Screening:

  1. Is informed, has been given ample time and opportunity to read about participation in the study and has signed and dated the written informed consent form approved by an Independent Ethics committee (IEC) prior to any study related activities
  2. Females ≥ 18 years
  3. Histologically confirmed and documented invasive breast cancer
  4. Breast cancer without evidence of distant metastases (Stage 4) based on staging work-up
  5. Chemotherapy naive, who have not received chemotherapy in the neoadjuvant setting and who are candidates for chemotherapy in the adjuvant setting of taxane/cyclophosphamide-based regimen, e.g., TAC, as background chemotherapy
  6. Zubrod/WHO/ECOG performance status ≤ 2

  7. Adequate bone marrow, hepatic, and renal function reserve as evidenced by:

     1. Hemoglobin ≥ 10 mg/dl
     2. ANC ≥ 1.5 x 10^9/L
     3. Platelet count of ≥ 100 x 10^9/L
     4. Total bilirubin ≤ 2 mg/dl
     5. Aspartate Aminotransferase (AST) and Alanine Aminotransferase (ALT) ≤ 3 x the upper limit of normal (ULN) of the reference lab
     6. Serum creatinine of ≤ 1.5 x ULN for reference lab or estimated glomerular filtration rate (eGFR) of ≥ 60 mg/min
  8. Body mass index (BMI) of 19 to 40 kg/m^2 , inclusive

  9. Subjects of childbearing potential, and their partners, agree to pregnancy prevention throughout the duration of the study (through the Follow-up Visit). Specific type of pregnancy prevention should be discussed with, and acceptable to, the treating oncologist in the context of the tumoral hormone receptor status. Subjects and their partners must agree to use of an effective method of contraception, to avoid impregnation of females throughout the course of the study

     Medically acceptable forms of birth control can include, with approval of the treating physician:

     1. Barrier methods (condom or diaphragm with spermicide)
     2. Intrauterine device (IUD)
     3. Hormone contraceptives (such as oral [pill], injection, skin patch, implant, cervical ring)
     4. Subjects using oral contraceptives must be on a stable regimen for at least 3 months prior to Screening. Sexually active subjects must use contraception while on HSP-130 from admission to the final Follow-up Visit
  10. Able to understand verbal or written instructions and comply with all study requirements, to communicate effectively with study personnel and is available for the planned duration of the study

Exclusion Criteria:

• A subject will NOT be eligible for study participation if any of the following criteria are met at Screening:

  1. Previous G-CSF exposure, including filgrastim, lenograstim, pegfilgrastim, lipegfilgrastim, granulocyte/macrophage colony stimulating growth factor (GM-CSF), or any other branded or biosimilar G-CSF
  2. Prior autologous stem cell harvest of any type
  3. Drug sensitivity, allergic reaction, or known hypersensitivity or idiosyncratic reaction to E. coli - derived proteins, filgrastim, other G-CSFs, or pegylated agents
  4. Known hypersensitivity to docetaxel, polysorbate 80, or doxorubicin
  5. For subjects receiving doxorubicin, no concurrent use of inhibitors and inducers of CYP3A4, CYP2D6, and/or P-gp or with trastuzumab due to increased risk of cardiac dysfunction
  6. Chemotherapy other than that included in this study (taxane/cyclophosphamide-based regimen, e.g., TAC or TC) or neoadjuvant chemotherapy; or known immunosuppressive agents including chronic oral corticosteroid use, or radiation therapy within 4 weeks of first dose of HSP-130, prior bone marrow or stem cell transplantation, or malignancy within 5 years
  7. Known HER2 + ( overexpressing breast cancer)
  8. Known triple negative (estrogen receptor-negative, progesterone receptor-negative and HER2-negative) breast cancer
  9. ≥ Grade 2 underlying neuropathy
  10. Current diagnosis of active tuberculosis or other severe infection, such as sepsis, abscesses or opportunistic infections
  11. Treatment with systemically active antibiotics within 72 hours before chemotherapy
  12. Known infection with HIV
  13. Known sickle cell disease
  14. Known severe persistent drug-induced myelosuppression
  15. New York Heart Association (NYHA) class III or IV heart failure, severe uncontrolled cardiac disease (unstable angina, clinically significant ECG abnormalities) or MI within the previous 6 months before the first administration of HSP-130
  16. Any malignancy other than breast cancer, with exception of adequately treated squamous or basal cell carcinoma of the skin or cervical carcinoma in situ, within 5 years before the first administration of the HSP-130
  17. Current or recent treatment (within 30 days before the first administration of the HSP-130) with any other investigational medicinal product
  18. Pregnancy or lactation; Subjects planning to be pregnant or to breastfeed before, during, or within 12 months after administration of the HSP-130 are not permitted to enroll in the study
  19. Received a live, live-attenuated, or non-live vaccine within 4 weeks before the first administration of the HSP-130
  20. Patient has evidence of any other coexisting disease or medical or psychological condition, metabolic dysfunction, physical examination finding or clinical lab finding giving reasonable suspicion of a disease or condition that contraindicated the use of an HSP-130, or patient is high risk for treatment complication

Contacts and Locations

Locations

Hungary

CRU Hungary Kft.,CRU Early Phase Unit, Miskolci Semmelweis Kórház és Egyetemi Oktató Kórház

Miskolc, BAZ Megye, Hungary, 3529

Debreceni Egyetem Klinikai Központ, ÁOK, Onkológiai Klinika

Debrecen, Hajdú-bihar Megye, Hungary, 4032

Országos Onkológiai Intézet

Budapest, Hungary, 1122

Spain

Hospital Universitario Arnau de Vilanova

Lleida, Cataluna, Spain, 25198

Hospital Universitario de Fuenlabrada, Servicio de oncologia

Fuenlanbrada, Madrid, Spain, 28942

START Madrid - CIOCC, Unidad de fases 1 planta 3, Hospital Universitario HM Sanchinarro

Madrid, Spain, 28050

Hospital Arnau de Vilanova. planta 6, unidad de Oncología

Valencia, Spain, 46015

Sponsors and Collaborators

Pfizer

Hospira, now a wholly owned subsidiary of Pfizer

Investigators

• Study Director: Pfizer CT.gov Call Center; Pfizer

  Study Documents (Full-Text)

Documents provided by Pfizer:

Study Protocol  [PDF] December 22, 2015

Statistical Analysis Plan  [PDF] December 11, 2017

More Information

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):

Yao HM, Jones SR, Morales S, Moosavi S, Zhang J, Freyman A, Ottery FD. Phase I/II study to assess the clinical pharmacology and safety of single ascending and multiple subcutaneous doses of PF-06881894 in women with non-distantly metastatic breast cancer. Cancer Chemother Pharmacol. 2021 Dec;88(6):1033-1048. doi: 10.1007/s00280-021-04355-6. Epub 2021 Oct 7.

• Responsible Party: Pfizer
• ClinicalTrials.gov Identifier: NCT02650193
• Other Study ID Numbers: ZIN-130-1504; C1221002 ( Other Identifier: Alias Study Number ); 2015-002057-35 ( EudraCT Number )
• First Posted: January 8, 2016
• Results First Posted: October 23, 2018
• Last Update Posted: October 23, 2018
• Last Verified: September 2018

Keywords provided by Pfizer:

HSP-130 Phase 1-2 Study in patients with Breast cancer

Additional relevant MeSH terms:

Breast Neoplasms; Neoplasms by Site; Neoplasms; Breast Diseases; Skin Diseases